一、日常关联交易基本情况 （一）日常关联交易概述 深圳市卫光生物制品股份有限公司（以下简称公司）于 2025 年 4 月 21 日召 开第三届董事会第三十二次会议、第三届监事会第二十五次会议审议通过了《关 于 2024 年度日常关联交易执行情况及预计 2025 年度日常关联交易的议案》。 公司及子公司基于实际经营需要，预计 2025 年与关联方武汉生物制品研究 所有限责任公司发生日常关联交易的金额为 100 万元，公司 2024 年实际发生的 日常关联交易金额为 2.88 万元。 证券代码:002880 证券简称:卫光生物 公告编号:2025-008 深圳市卫光生物制品股份有限公司 关于 2024 年度日常关联交易执行情况及 预计 2025 年度日常关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 公司名称：武汉生物制品研究所有限责任公司 公司住所：武汉市江夏区郑店黄金工业园路1号 根据《深圳证券交易所股票上市规则》《公司章程》等的相关规定，本事 项无需提交公司股东大会审议。 注册资本：456,400万元人民币 | | | | 序 | 关联方 | ...

深圳市卫光生物制品股份有限公司 2024年度内部控制自我评价报告 根据《企业内部控制基本规范》及其配套指引，以及《深圳证券交易所上市公 司自律监管指引》的相关规定，结合公司内部控制制度，在内部控制日常监督和 专项监督的基础上，董事会对公司2024年12月31日（内控评价报告基准日）的内 部控制有效性进行了全面评价。 一、关于内控责任的声明 董事会及全体董事保证本报告内容不存在任何虚假记载、误导性陈述或重大 遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带责任。 按照企业内部控制规范体系的规定，建立健全并有效实施内部控制，评价其有 效性并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和 实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。 公司内部控制目标是合理保证经营管理合法合规、资产安全、财务报告及相关 信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的 固有局限性，故仅能为实现上述目标提供合理保证。此外，情况的变化可能导致 内部控制变得不恰当，或对控制政策和程序的遵循程度降低，因此根据内部控制 评价结果推测未来内部控制的有效性具有一定的风险。 二、内 ...

一、监事会工作情况 2024 年，监事会严格按照所赋予的职责，从切实维护公司和全体股东利益出 发，认真履行监督职责，共召开 7 次监事会会议，列席 9 次董事会会议及出席 3 次股东大会，通过了解公司各项重要决策的形成过程，较好地履行了监事会知情、 监督和检查的职能。2024 年监事会审议议案如下： | 序号 | 会议名称 | | 会议时间 | | | 审 议 议 案 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 第三届监事会第 | 2024 | 年 | 2 | | 《关于〈深圳市卫光生物制品股份有限公司第三期员工持股计划 | | | 十八次会议 | 月 | 5 日 | | | （草案）及其摘要〉的议案》《关于〈深圳市卫光生物制品股份 | | | | | | | | 有限公司第三期员工持股计划管理办法〉的议案》 | | 2 | 第三届监事会第 | 2024 | 年 | 3 | | 《关于<深圳市卫光生物制品股份有限公司第三期员工持股计划 | | | 十九次会议 | 月 | 14 日 | | | （草案修订稿）>及其摘要的议案》《关于<深圳市卫光生物制品 ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-009 深圳市卫光生物制品股份有限公司 2024 年度股东大会通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）第三届董事会第三十二 次会议决定于 2025 年 5 月 19 日在广东省深圳市光明区光明街道光侨大道 3402 号公司综合楼 3 楼会议室召开 2024 年度股东大会（以下简称本次股东大会）。 现就召开本次股东大会有关事宜通知如下： 一、召开会议的基本情况 1.股东大会届次：2024 年度股东大会。 2.股东大会的召集人：公司董事会。 3.会议召开的合法合规性：公司第三届董事会第三十二次会议审议通过《关 于召开 2024 年度股东大会的议案》，决定召开公司 2024 年度股东大会。本次股 东大会的召开符合有关法律法规和《公司章程》的规定。 4.会议召开的日期、时间： （1）现场会议召开时间：2025 年 5 月 19 日 14:30。 （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 5 月 19 日 ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-004 1.审议通过了《关于 2024 年年度报告及其摘要的议案》； 经审核，监事会认为董事会编制和审议公司《2024年年度报告》及其摘要的 程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：同意票3票，反对票0票，弃权票0票 本议案尚需提交公司2024年度股东大会审议。 深圳市卫光生物制品股份有限公司 第三届监事会第二十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市卫光生物制品股份有限公司（以下简称公司）第三届监事会第二十五 次会议于 2025 年 4 月 21 日在公司综合楼三楼会议室以现场结合通讯方式召开， 会议应出席监事 3 名，实际出席监事 3 名。本次会议由监事会主席邬玉生先生主 持，会议的召集、召开和表决程序符合《公司法》和《公司章程》的规定。 二、监事会会议审议情况 会议经逐项审议，书面表决，审议通过了如下议案： 表决结果：同意3票，反 ...

Financial Performance - Revenue for Q1 2025 was CNY 225,002,020.97, a decrease of 0.57% compared to CNY 226,302,459.95 in the same period last year[5] - Net profit attributable to shareholders was CNY 43,768,169.85, down 6.54% from CNY 46,831,857.32 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.1930, reflecting a decrease of 6.54% compared to CNY 0.2065 in the prior year[5] - Total operating revenue for the current period was ¥225,002,020.97, a decrease of 0.57% from ¥226,302,459.95 in the previous period[18] - Net profit for the current period was ¥43,723,532.62, down 6.4% from ¥46,793,784.04 in the previous period[19] - The total comprehensive income for the current period is CNY 43,723,532.62, compared to CNY 46,793,784.04 in the previous period, reflecting a decrease of approximately 4.5%[20] Cash Flow - Net cash flow from operating activities improved significantly to CNY 21,232,808.69, a 281.18% increase from a negative CNY 11,719,385.39 in the previous year[5] - Cash inflows from operating activities totaled CNY 266,502,826.78, an increase of approximately 16.9% from CNY 227,799,769.87 in the previous period[22] - Cash inflows from investing activities amounted to CNY 55,360,205.56, while cash outflows were CNY 30,351,184.34, resulting in a net cash flow of CNY 25,009,021.22, compared to a net outflow of CNY 46,345,234.02 in the previous period[22] - Cash inflows from financing activities were CNY 100,000,000.00, down from CNY 154,378,416.90 in the previous period, reflecting a decrease of about 35.2%[22] - The net cash flow from financing activities is -CNY 15,911,820.57, a significant decline compared to a net inflow of CNY 142,930,683.34 in the previous period[22] - The ending cash and cash equivalents balance is CNY 305,060,446.40, down from CNY 336,343,535.12 in the previous period, indicating a decrease of approximately 9.3%[22] Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 3,290,684,004.06, a slight decrease of 0.21% from CNY 3,297,444,233.19 at the end of the previous year[5] - Total liabilities decreased to ¥1,002,724,006.27 from ¥1,053,207,768.02, a reduction of 4.8%[16] - The company's equity attributable to shareholders increased to ¥2,255,193,500.99 from ¥2,211,425,331.14, an increase of 1.97%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,540[10] - The largest shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of the shares[10] Other Financial Metrics - Government subsidies recognized in the current period amounted to CNY 1,197,892.46, contributing positively to the financial results[7] - Other income increased by 44.79% to CNY 2,284,038.25, primarily due to an increase in government subsidies received[8] - Research and development expenses were ¥11,551,806.32, down 5.5% from ¥12,223,999.54 in the previous period[19] - The company reported a credit impairment loss of ¥343,987.15, compared to a loss of ¥503,396.46 in the previous period[19] Accounting and Audit - The company has not undergone an audit for the first quarter report[23] - The company will implement new accounting standards starting from 2025[24]

Financial Performance - The company's operating revenue for 2024 reached ¥1,203,192,257.65, representing a 14.75% increase compared to ¥1,048,502,589.77 in 2023[21] - The net profit attributable to shareholders for 2024 was ¥253,516,220.45, up 15.95% from ¥218,651,341.25 in 2023[21] - The net profit after deducting non-recurring gains and losses was ¥263,514,572.94, reflecting a 25.97% increase from ¥209,192,977.37 in 2023[21] - The basic earnings per share for 2024 was ¥1.1178, a 15.94% increase from ¥0.9641 in 2023[21] - The total assets at the end of 2024 amounted to ¥3,297,444,233.19, a 14.62% increase from ¥2,876,778,757.84 at the end of 2023[21] - The company's cash flow from operating activities decreased by 55.33% to ¥177,765,211.48 from ¥397,938,765.23 in 2023[21] - The weighted average return on equity for 2024 was 11.99%, up from 11.37% in 2023[21] - The company achieved a historical high in revenue for 2024, reaching approximately CNY 1.203 billion, a year-on-year increase of 14.75%[46] Dividend and Shareholder Information - The company plans to distribute a cash dividend of ¥2 per 10 shares, totaling ¥45,360,000 based on 226,800,000 shares[7] - The total number of shares for the dividend distribution is based on 226,800,000 shares, with a distributable profit of 1,226,520,067.15 CNY[141] - The company has implemented a third employee stock ownership plan, with 787,000 shares purchased, accounting for 0.35% of the total share capital[144] - The cash dividend policy is compliant with the company's articles of association and has clear standards and procedures[140] Market and Industry Trends - The blood products industry in China is expected to see a significant increase in per capita demand due to aging population trends and improved healthcare resources[34] - The market for blood products is projected to grow as the number of patients increases and the usage rates of immunoglobulins and albumin rise[33] - The blood products industry faces high entry barriers and strict regulatory oversight, limiting the number of operational companies in the market[32] - The blood product industry is experiencing ongoing consolidation, with the top five companies holding a significant market share, indicating a trend towards increased industry concentration[37] Product Development and R&D - The company aims to enhance the comprehensive utilization rate of plasma through continuous product research and development[35] - The company is focusing on developing recombinant products to supplement blood-derived products, which are limited by plasma supply[36] - The company is developing new products, including a prothrombin complex concentrate (PCC) expected to enhance product variety and improve plasma utilization rates[67] - The company holds 64 patents, including 24 invention patents, reflecting its strong commitment to research and development in the biopharmaceutical sector[50] Operational Efficiency and Management - The company is focusing on improving quality management efficiency through the implementation of nine projects, including a quality management system and AI video monitoring[94] - The company aims to enhance its core competitiveness through four major actions: scale, efficiency, effectiveness, and market value improvements[92] - The company plans to implement a strategy to increase plasma source development and improve internal management to enhance plasma collection quality and service levels[93] Risks and Challenges - The company has highlighted potential risks in its future operations, which investors should be aware of[5] - The company faces risks related to insufficient raw plasma supply due to stricter regulations on establishing new plasma collection stations[98] - The company faces risks in new product development due to long research cycles influenced by technology, design, clinical outcomes, budget, policies, and market demand[99] - Potential safety risks exist in blood products due to unknown pathogens, despite strict adherence to national regulations and advanced collection technologies[100] Governance and Leadership - The company maintains a robust governance structure, ensuring independence from its controlling shareholder in operations, finance, and assets[109] - The company experienced a leadership change with the resignation of Vice General Manager Xu Qiang due to retirement on August 21, 2024[115] - The company is in the process of nominating candidates for the new board of directors and supervisory board, with the election postponed to ensure continuity[114] - The company’s chairman, Zhang Zhan, has been in position since December 2021, ensuring stable leadership[117] Environmental Responsibility - The company has complied with various environmental protection laws and regulations, ensuring adherence to industry standards[152] - The company has successfully obtained environmental impact assessments and permits for its production facilities, with valid licenses extending to 2027[153] - The company has achieved ISO14001 environmental management system certification in 2021 and successfully passed recertification in 2024, promoting low-carbon and energy-saving initiatives[159] Employee and Community Engagement - The company has provided various employee benefits, including social insurance, housing funds, and annual health check-ups[136] - The training program for employees has been executed well, focusing on corporate culture, professional skills, and management capabilities, although improvements are needed in coverage and relevance[137] - The company has engaged in social responsibility activities, with approximately 150 registered volunteers participating in 9 events, contributing over 200 volunteer service hours[160]

证券代码:002880 证券简称:卫光生物 公告编号:2025-003 深圳市卫光生物制品股份有限公司 第三届董事会第三十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市卫光生物制品股份有限公司（以下简称公司）第三届董事会第三十二 次会议于2025年4月21日在公司综合楼三楼会议室以现场结合通讯方式召开。本 次会议应参加董事8名，实际参加董事8名，公司监事及高级管理人员列席了会议。 本次会议由董事长张战先生主持，会议的召集、召开和表决程序符合《公司法》 等有关法律、法规及《公司章程》的规定。 与会董事认真听取了公司总经理所作的《2024年度总经理工作报告》，认为 该报告客观、真实地反映了2024年度公司落实股东大会及董事会决议、管理生产 经营、执行公司各项管理制度等方面工作的情况。 二、董事会会议审议情况 会议经逐项审议，书面表决，审议通过了以下议案： 1.审议通过了《关于2024年年度报告及其摘要的议案》； 公司《2024年年度报告》及其摘要具体内容详见同日刊登在指定信息披露媒 体及巨潮资讯网(www.cnin ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-006 深圳市卫光生物制品股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、审议程序 深圳市卫光生物制品股份有限公司（以下简称公司）于 2025 年 4 月 21 日召 开第三届董事会第三十二次会议、第三届监事会第二十五次会议，审议通过了《关 于 2024 年度利润分配预案的议案》，上述议案尚需提交公司 2024 年度股东大会 审议。现将该预案有关情况公告如下： 二、利润分配方案的基本情况 根据大信会计师事务所（特殊普通合伙）出具的 2024 年度审计报告，2024 年，公司实现合并报表归属于上市公司普通股股东净利润 253,516,220.45 元，母 公司报表净利润 245,437,546.46 元。根据《公司章程》的相关规定，公司分配当 年税后利润时，应当提取利润的 10%列入公司法定公积金。公司法定公积金累计 额为公司注册资本的 50%以上的，可以不再提取。2024 年度，公司提取法定公 积金 24,543,754.65 元。公司 2 ...

卫光生物（002880）公告，2024年营业收入12.03亿元，同比增长14.75%。归属于上市公司股东的净利 润2.54亿元，同比增长15.95%。基本每股收益1.12元/股，同比增长15.94%。公司拟向全体股东每10股派 发现金红利2元(含税)，送红股0股(含税)，不以公积金转增股本。 ...